Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GLYC - GlycoMimetics Inc


IEX Last Trade
0.1738
0.001   0.345%

Share volume: 572,335
Last Updated: Fri 30 Aug 2024 09:28:01 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.17
0.00
0.35%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
25%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-7.21%
1 Month
-19.13%
3 Months
-35.66%
6 Months
-93.86%
1 Year
-88.98%
2 Year
-76.67%
Key data
Stock price
$0.17
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.16 - $3.53
52 WEEK CHANGE
-$0.89
MARKET CAP 
11.369 M
YIELD 
N/A
SHARES OUTSTANDING 
64.484 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/01/2024
BETA 
0.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,052,025
AVERAGE 30 VOLUME 
$1,371,086
Company detail
CEO: Rachel King
Region: US
Website: http://glycomimetics.com/
Employees: 54
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.

Recent news